☆ 4.6 Article

Clinical course impacts early kinetics, magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

CELL REPORTS MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Multidisciplinary Sciences

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Peter B. Gilbert et al.

Summary: In the COVE phase 3 clinical trial, neutralizing and binding antibodies were measured in vaccine recipients to determine their correlation with COVID-19 risk and vaccine efficacy. The results showed that these immune markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Postvaccination neutralization titers of 10, 100, and 1000 correlated with estimated vaccine efficacies of 78%, 91%, and 96% respectively.

SCIENCE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

添加到收藏夹

Article Immunology

Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans

Anu Haveri et al.

Summary: According to a study, 89% of individuals infected with the WT SARS-CoV-2 strain still had neutralizing antibodies against the WT virus for at least 13 months, and 97% had S-IgG antibodies. On the other hand, only 36% of individuals still had N-IgG antibodies at 13 months. Patients with severe infections had higher antibody levels and are likely to remain seropositive for a longer period of time. Lower neutralizing antibody titers against variants compared to the WT virus, especially after a mild disease, suggest reduced protection against VOCs.

EUROPEAN JOURNAL OF IMMUNOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler et al.

Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.

NATURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

S. F. Lumley et al.

Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Immunology

Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission

Young-Il Kim et al.

Summary: The study found that ferrets with high NAb titres after SARS-CoV-2 infection showed attenuated viral replication and rapid viral clearance upon reinfection, while ferrets with low NAb titres were more prone to reinfection.

EMERGING MICROBES & INFECTIONS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Adam K. Wheatley et al.

Summary: The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Antibody, B cell, and T cell responses decline over the first 4 months post-infection, while S-specific IgG(+) memory B cells consistently accumulate. The study suggests that natural infection may only provide transient protection at a population level, highlighting the need for more immunogenic and durable vaccines.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

Benjamin Trinite et al.

Summary: The levels of neutralizing antibodies significantly increase with disease severity in COVID-19 patients. Hospitalized individuals have higher titers compared to those with mild symptoms or asymptomatic, with no significant impact from age, gender, or treatment on the neutralizing titers.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Microbiology

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Kanika Vanshylla et al.

Summary: The study reveals a wide spectrum of neutralizing antibody response to SARS-CoV-2, with sustained antibodies in the majority of individuals with mild COVID-19 for up to 10 months after infection.

CELL HOST & MICROBE (2021)

添加到收藏夹

Article Microbiology

Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern

Liane Dupont et al.

Summary: The design and rollout of COVID-19 vaccines should consider the durability and cross-neutralizing potential of antibodies against SARS-CoV-2 and emerging variants. Studies on convalescent sera show that cross-neutralizing activity can last up to 305 days post onset of symptoms, with differences in neutralization potency against variants decreasing over time due to antibody maturation.

NATURE MICROBIOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients

Juan Manuel Carreno et al.

Summary: The study found that currently circulating viral variants, including Iota and Delta, show only minimal decreases in neutralization, while the Lambda sub-variant exhibits a significant reduction in neutralization, followed by Beta and Alpha (E484K). Overall, mRNA SARS-CoV-2 vaccines may still be effective against these viral variants, and receptor binding domain and spike binding antibody tests may retain specificity in the face of evolving SARS-CoV-2 diversity.

EBIOMEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Article Virology

SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies

Thomas Theo Brehm et al.

Summary: Only a few reports on SARS-CoV-2 reinfections with limited immunological and virological data have been published. Our study found that a moderate immune response after the first infection, rather than viral escape, may lead to reinfection and live virus shedding.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

Jackson S. Turner et al.

Summary: The study found that individuals who had recovered from mild SARS-CoV-2 infections showed rapid decline of serum anti-SARS-CoV-2 spike protein antibodies in the first 4 months after infection, followed by a more gradual decrease over the following 7 months but remaining detectable at least 11 months after infection. This suggests that mild infection with SARS-CoV-2 can induce robust antigen-specific, long-lived humoral immune memory in humans.

NATURE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Zijun Wang et al.

Summary: Despite challenges posed by COVID-19 variants, convalescent individuals receiving mRNA vaccines exhibit robust and long-lasting immune responses against circulating SARS-CoV-2 variants, providing hope for effective control of the pandemic.

NATURE (2021)

添加到收藏夹

Article Immunology

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen A. Earle et al.

Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

VACCINE (2021)

添加到收藏夹

Article Virology

Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals

Benjamin Trinite et al.

Summary: The study found that the time from natural infection and the nature of the infecting variant determined cross-neutralization; Uninfected vaccinees showed a small reduction in neutralization against the B.1.1.7 variant; Previously infected individuals developed more robust neutralizing responses against B.1.1.7 after vaccination, indicating that vaccines can enhance the neutralization breadth conferred by natural infection.

VIRUSES-BASEL (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses

Natalia Ortega et al.

Summary: Long-term kinetics of antibodies to SARS-CoV-2 were examined in a cohort of health care workers, showing stable levels over time with an increase in anti-spike antibody levels around 150 days post-symptom onset. Additionally, asymptomatic individuals had significantly higher levels of IgG and IgA to HCoV compared to symptomatic individuals, suggesting a potential protective effect of pre-existing cross-reactive HCoVs antibodies against SARS-CoV-2 infection and COVID-19 disease.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection

Floriane Gallais et al.

Summary: The study revealed a triphasic kinetic model of SARS-CoV-2 antibodies in convalescent individuals, showing long-term persistence and reduced risk of reinfection. Vaccination significantly increased antibody titers, enhancing protection against variants.

EBIOMEDICINE (2021)

添加到收藏夹

Article Immunology

Longevity of Middle East Respiratory Syndrome Coronavirus Antibody Responses in Humans, Saudi Arabia

Abeer N. Alshukairi et al.

Summary: The study of antibody responses in MERS-CoV infection survivors in Saudi Arabia showed the presence of specific neutralizing antibodies up to 6 years postinfection. This finding provides crucial information for the development of MERS-CoV vaccines.

EMERGING INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

Edwards Pradenas et al.

Summary: The study found that individuals with mild or asymptomatic infections experienced an insignificant decrease in neutralizing activity, which persisted for 6 months after symptom onset or diagnosis. Hospitalized individuals exhibited higher neutralizing titers, which decreased rapidly at first but significantly slowed down after day 80, remaining higher than those with mild symptoms at 6 months. This slow decline in neutralizing activity contrasted with the constant decrease in anti-RBD, S2, or NP antibody titers over the follow-up period.

MED (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity

Jorge Carrillo et al.

Summary: The magnitude and quality of humoral responses to SARS-CoV-2 are associated with clinical outcomes, with different individuals showing variable responses. Rapid production of antibodies, including neutralizing antibodies, against viral proteins like the Spike glycoprotein, targeting the receptor binding domain (RBD), is crucial for protection and vaccine development. Duration of humoral responses and possible transient immunity remain unknown, with cases of reinfection reported.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

添加到收藏夹

Article Immunology

Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019

Juanjuan Zhao et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Letter Infectious Diseases

Profile of specific antibodies to SARS-CoV-2: The first report

Ai Tang Xiao et al.

JOURNAL OF INFECTION (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Xiuyuan Ou et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Immunology

Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients

Xiaoli Wang et al.

CLINICAL INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Quan-Xin Long et al.

NATURE MEDICINE (2020)

添加到收藏夹

Letter Medicine, General & Internal

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

F. Javier Ibarrondo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Microbiology

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

Amin Addetia et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Seasonal coronavirus protective immunity is short-lasting

Arthur W. D. Edridge et al.

NATURE MEDICINE (2020)

添加到收藏夹

Review Multidisciplinary Sciences

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Angkana T. Huang et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

添加到收藏夹

Article Cell Biology

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

Mehul S. Suthar et al.

CELL REPORTS MEDICINE (2020)

添加到收藏夹

Article Immunology

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2

Danielle E. Anderson et al.

EMERGING MICROBES & INFECTIONS (2020)

添加到收藏夹

Review Immunology

The Maintenance of Memory Plasma Cells

Laleh Khodadadi et al.

FRONTIERS IN IMMUNOLOGY (2019)

添加到收藏夹

Article Immunology

Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia

Hail M. Al-Abdely et al.

EMERGING INFECTIOUS DISEASES (2019)

添加到收藏夹

Article Immunology

MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015

Pyoeng Gyun Choe et al.

EMERGING INFECTIOUS DISEASES (2017)

添加到收藏夹

Review Immunology

Plasma cell and memory B cell differentiation from the germinal center

Dan Suan et al.

CURRENT OPINION IN IMMUNOLOGY (2017)

添加到收藏夹

Article Immunology

Persistence of Antibodies against Middle East Respiratory Syndrome Coronavirus

Daniel C. Payne et al.

EMERGING INFECTIOUS DISEASES (2016)

添加到收藏夹

Article Immunology

Kinetics of Serologic Responses to MERS Coronavirus Infection in Humans, South Korea

Wan Beom Park et al.

EMERGING INFECTIOUS DISEASES (2015)

添加到收藏夹

Article Infectious Diseases

Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients

Lifeng Liu et al.

SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2011)

添加到收藏夹

Article Immunology

A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity

Sonsoles Sanchez-Palomino et al.

VACCINE (2011)

添加到收藏夹

Review Immunology

Correlates of Protection Induced by Vaccination

Stanley A. Plotkin

CLINICAL AND VACCINE IMMUNOLOGY (2010)

添加到收藏夹

Letter Medicine, General & Internal

Disappearance of antibodies to SARS-associated coronavirus after recovery

Wu-Chun Cao et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

添加到收藏夹

Review Immunology

Competence and competition:: the challenge of becoming a long-lived plasma cell

Andreas Radbruch et al.

NATURE REVIEWS IMMUNOLOGY (2006)

添加到收藏夹

Article Respiratory System

Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance

HY Mo et al.

RESPIROLOGY (2006)

添加到收藏夹

Article Immunology

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes

NJ Temperton et al.

EMERGING INFECTIOUS DISEASES (2005)

添加到收藏夹

Article Immunology

Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection

YC Nie et al.

JOURNAL OF INFECTIOUS DISEASES (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.